SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)


Share post:


Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies' weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy.


The post SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY) first appeared on


Please enter your comment!
Please enter your name here

Related articles

11+ Best Places to Find Search Engine Evaluator Jobs in 2024

If you're looking for an interesting way to work from home on your own schedule, this list...

Apple is the EU's First Target of New Digital Competition Rules

The Digital Markets Act is the 27-nation bloc's attempt to keep big tech "gatekeepers" from cornering markets.

How to Invest $10k Right Now (Top 5 Tips From a NYT Bestseller)

Investing is the surefire way to wealth. And if you’re holding onto $10k, you’re already ahead of...

Why High Retention Could Actually Be a Red Flag for Your Company

Re/Max co-founder and chairman Dave Liniger walks through one of his biggest lessons in entrepreneurship.